Strs Ohio Buys New Holdings in Xeris Biopharma Holdings, Inc. $XERS

Key Points

• Strs Ohio has acquired a new stake in Xeris Biopharma Holdings, Inc., purchasing 60,900 shares valued at approximately $334,000 during the first quarter.
• Analysts have mixed ratings on Xeris Biopharma, with five giving it a Buy rating and one a Hold rating, while the stock currently has an average target price of $7.08.
• Xeris Biopharma's shares opened at $7.91 and reported earnings of ($0.01) per share, surpassing analysts' expectations of ($0.03) EPS for their most recent quarter.

Strs Ohio purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 60,900 shares of the company's stock, valued at approximately $334,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC increased its stake in Xeris Biopharma by 13.4% in the first quarter. AQR Capital Management LLC now owns 946,766 shares of the company's stock valued at $5,198,000 after acquiring an additional 111,826 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in Xeris Biopharma by 92.1% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 31,254 shares of the company's stock valued at $172,000 after purchasing an additional 14,986 shares in the last quarter. Nuveen LLC bought a new stake in shares of Xeris Biopharma in the 1st quarter valued at approximately $12,240,000. Millennium Management LLC grew its stake in shares of Xeris Biopharma by 34.8% in the 4th quarter. Millennium Management LLC now owns 1,948,552 shares of the company's stock valued at $6,606,000 after purchasing an additional 502,853 shares during the period. Finally, Two Sigma Advisers LP acquired a new position in shares of Xeris Biopharma in the 4th quarter worth approximately $47,000. Institutional investors own 42.75% of the company's stock.

Xeris Biopharma Stock Up 0.6%

Shares of Xeris Biopharma stock opened at $7.91 on Wednesday. The business has a fifty day simple moving average of $6.85 and a 200 day simple moving average of $5.47. The stock has a market cap of $1.28 billion, a PE ratio of -37.66 and a beta of 0.13. Xeris Biopharma Holdings, Inc. has a 12 month low of $2.69 and a 12 month high of $8.35.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to the consensus estimate of $64.58 million. Analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Wall Street Zen lowered Xeris Biopharma from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 5th. HC Wainwright began coverage on shares of Xeris Biopharma in a research note on Tuesday, August 12th. They issued a "buy" rating and a $10.00 target price on the stock. Finally, Leerink Partners upped their target price on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an "outperform" rating in a report on Tuesday, August 19th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, Xeris Biopharma has an average rating of "Moderate Buy" and an average target price of $7.08.

Insider Activity

In other news, Director Marla Persky sold 15,500 shares of Xeris Biopharma stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $7.72, for a total transaction of $119,660.00. Following the transaction, the director directly owned 142,000 shares of the company's stock, valued at $1,096,240. This trade represents a 9.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey W. Sherman sold 42,232 shares of the business's stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $7.92, for a total transaction of $334,477.44. Following the completion of the transaction, the director directly owned 219,188 shares of the company's stock, valued at $1,735,968.96. This trade represents a 16.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold 207,732 shares of company stock worth $1,550,437 over the last quarter. 4.56% of the stock is owned by insiders.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.